Impel NeuroPharma said today that it raised $67.5 million in a Series D financing round, with investments from KKR, Norwest Venture Partners, Vivo Capital, 5Am Ventures and venBio Partners.
The Seattle-based company plans to use the round’s proceeds to support clinical development efforts for its intranasal drug-delivery device technology.
Get the full story at our sister site, Drug Delivery Business News.
The post Impel NeuroPharma raises $68m for CNS drug-device tech appeared first on MassDevice.